Abstract
Background: The Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADASCog) remains the most widely used test of longitudinal cognitive functioning in Alzheimer’s disease (AD) clinical trials. Unlike most neuropsychological tests, the ADAS-Cog source documentation worksheets are not uniform across clinical trials, and vary by document layout, inclusion of administration and/or scoring instructions, and documentation of subtest scoring (e.g., recording correct versus incorrect scores), among other differences. Many ADAS-Cog test administrators (raters) participate in multiple AD trials and switching between different ADAS-Cog worksheets may increase the likelihood of administration and/or scoring mistakes that lessen the reliability of the instrument. An anonymous online survey sought raters’ experiences with ADAS-Cog worksheets and their opinions on the design and content of the worksheets.
Results: Results of the survey indicated preference for structure and standardization of the ADASCog worksheets, which has been considered in the development of a standard ADAS-Cog source document by the Alzheimer’s Disease Cooperative Study (ADCS) Working Group.Keywords: Alzheimer's Disease Assessment Scale (ADAS), Alzheimer’s disease, clinical trials, outcomes, rater, survey.
Current Alzheimer Research
Title:Optimizing ADAS-Cog Worksheets: A Survey of Clinical Trial Rater s’ Perceptions
Volume: 14 Issue: 9
Author(s): Stephen M. Meyer, Kristina A. Bertzos, Magdalena Perez, Donald J. Connor*, Kimberly Schafer and Sarah Walter
Affiliation:
- Consultants in Cognitive and Clinical Trials,United States
Keywords: Alzheimer's Disease Assessment Scale (ADAS), Alzheimer’s disease, clinical trials, outcomes, rater, survey.
Abstract: Background: The Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADASCog) remains the most widely used test of longitudinal cognitive functioning in Alzheimer’s disease (AD) clinical trials. Unlike most neuropsychological tests, the ADAS-Cog source documentation worksheets are not uniform across clinical trials, and vary by document layout, inclusion of administration and/or scoring instructions, and documentation of subtest scoring (e.g., recording correct versus incorrect scores), among other differences. Many ADAS-Cog test administrators (raters) participate in multiple AD trials and switching between different ADAS-Cog worksheets may increase the likelihood of administration and/or scoring mistakes that lessen the reliability of the instrument. An anonymous online survey sought raters’ experiences with ADAS-Cog worksheets and their opinions on the design and content of the worksheets.
Results: Results of the survey indicated preference for structure and standardization of the ADASCog worksheets, which has been considered in the development of a standard ADAS-Cog source document by the Alzheimer’s Disease Cooperative Study (ADCS) Working Group.Export Options
About this article
Cite this article as:
Meyer M. Stephen , Bertzos A. Kristina , Perez Magdalena , Connor J. Donald*, Schafer Kimberly and Walter Sarah , Optimizing ADAS-Cog Worksheets: A Survey of Clinical Trial Rater s’ Perceptions, Current Alzheimer Research 2017; 14 (9) . https://dx.doi.org/10.2174/1567205014666170417122744
DOI https://dx.doi.org/10.2174/1567205014666170417122744 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (Thematic Issue: Regulating the CNS Grand Regulator; N-methyl-D-aspartate Receptor-Mediated Neurotransmission)
Current Pharmaceutical Design Visual and Quantitative Assessment of COVID-19 Pneumonia on Chest CT: The Relationship with Disease Severity and Clinical Findings
Current Medical Imaging Nanoparticle-Based Gene Therapy Intervention for Stroke Treatment: A Systematic Review
Current Gene Therapy Asthma-COPD Overlap: A more Simplistic Approach
Current Respiratory Medicine Reviews Assessing Medication Problems in those ≥ 65 Using the STOPP and START Criteria
Current Aging Science Tau Truncation is a Productive Posttranslational Modification of Neurofibrillary Degeneration in Alzheimer’s Disease
Current Alzheimer Research Stem Cell Pharmacogenomics
Current Topics in Medicinal Chemistry Recent Patents, Formulation and Characterization of Nanoliposomes
Recent Patents on Drug Delivery & Formulation Spirocyclohexadienones as an Uncommon Scaffold for Acetylcholinesterase Inhibitory Activity
Medicinal Chemistry Computational Investigation on Tyrosine to Alanine Mutations Delaying the Early Stage of α-Synuclein Aggregation
Current Proteomics Dampening the Progression of Dementia
Current Neurovascular Research Mineralocorticoid Antagonists in ESRD: An Overview of Clinical Trial Evidence
Current Vascular Pharmacology Cyclooxygenases in the Central Nervous System: Implications for Treatment of Neurological Disorders
Current Pharmaceutical Design Vascular Contribution to Alzheimer Disease: Predictors of Rapid Progression
CNS & Neurological Disorders - Drug Targets Acetylcholinesterase Inhibitor Donepezil Effects on Plasma β-Hydroxybutyrate Levels in the Treatment of Alzheimer’s Disease
Current Alzheimer Research Has the Amyloid Cascade Hypothesis for Alzheimers Disease been Proved?
Current Alzheimer Research An Exposition of <sup>11</sup>C and <sup>18</sup>F Radiotracers Synthesis for PET Imaging
Current Radiopharmaceuticals Serotonin and its Receptors in the Human CNS with New Findings - A Mini Review
Current Medicinal Chemistry CNS Drug Delivery Systems: Novel Approaches
Recent Patents on Drug Delivery & Formulation Lipoxygenase: An Emerging Target for Stroke Therapy
CNS & Neurological Disorders - Drug Targets